Roche Holding AG
RHO6
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.30 | 16.50 | -0.18% |
| CAC 40 | 8,500.73 | 101.95 | 1.21% |
| DAX 40 | 24,963.37 | 28.60 | -0.11% |
| Dow JONES (US) | 48,804.06 | 821.91 | -1.66% |
| FTSE 100 | 10,676.69 | 8.05 | -0.08% |
| HKSE | 26,590.32 | 491.59 | -1.82% |
| NASDAQ | 22,627.27 | 258.79 | -1.13% |
| Nikkei 225 | 57,321.09 | 495.39 | 0.87% |
| NZX 50 Index | 13,532.31 | 111.88 | 0.83% |
| S&P 500 | 6,837.75 | 71.76 | -1.04% |
| S&P/ASX 200 | 9,022.30 | 12.10 | -0.13% |
| SSE Composite Index | 4,117.41 | 35.34 | 0.87% |